Debra Tompson

1.0k total citations
28 papers, 810 citations indexed

About

Debra Tompson is a scholar working on Molecular Biology, Psychiatry and Mental health and Oncology. According to data from OpenAlex, Debra Tompson has authored 28 papers receiving a total of 810 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 11 papers in Psychiatry and Mental health and 10 papers in Oncology. Recurrent topics in Debra Tompson's work include Epilepsy research and treatment (8 papers), Pharmacological Effects and Toxicity Studies (7 papers) and Cell death mechanisms and regulation (5 papers). Debra Tompson is often cited by papers focused on Epilepsy research and treatment (8 papers), Pharmacological Effects and Toxicity Studies (7 papers) and Cell death mechanisms and regulation (5 papers). Debra Tompson collaborates with scholars based in United Kingdom, United States and Canada. Debra Tompson's co-authors include Christopher Crean, Nicola Scott, Paul P. Tak, Kathleen Weisel, Scott B. Berger, Sarah A. Job, Florian Then Bergh, Caryl Schwartzbach, Robert A. Brown and Richard Grove and has published in prestigious journals such as PLoS ONE, Pharmaceutical Research and Epilepsia.

In The Last Decade

Debra Tompson

28 papers receiving 774 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Debra Tompson United Kingdom 13 402 194 123 99 97 28 810
Eunice Yuen United States 18 320 0.8× 47 0.2× 97 0.8× 64 0.6× 97 1.0× 47 872
Ming Sun China 20 355 0.9× 109 0.6× 24 0.2× 80 0.8× 70 0.7× 49 938
Danilo Croci Italy 17 265 0.7× 101 0.5× 230 1.9× 225 2.3× 66 0.7× 24 902
Carol Donovan United States 14 350 0.9× 281 1.4× 70 0.6× 44 0.4× 104 1.1× 20 996
Smita Kshirsagar United States 11 431 1.1× 58 0.3× 285 2.3× 58 0.6× 227 2.3× 17 968
Maria B. Ræder Norway 17 526 1.3× 37 0.2× 132 1.1× 44 0.4× 67 0.7× 20 1.3k
Rosalin Arends United States 14 214 0.5× 79 0.4× 40 0.3× 63 0.6× 105 1.1× 22 1.0k
Sandrine Vuillaumier‐Barrot France 21 858 2.1× 236 1.2× 32 0.3× 50 0.5× 57 0.6× 54 1.3k
Jozef Hertecant United Arab Emirates 19 498 1.2× 61 0.3× 18 0.1× 70 0.7× 100 1.0× 50 995
Ugochi Emeribe United States 12 240 0.6× 61 0.3× 93 0.8× 17 0.2× 51 0.5× 24 902

Countries citing papers authored by Debra Tompson

Since Specialization
Citations

This map shows the geographic impact of Debra Tompson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Debra Tompson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Debra Tompson more than expected).

Fields of papers citing papers by Debra Tompson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Debra Tompson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Debra Tompson. The network helps show where Debra Tompson may publish in the future.

Co-authorship network of co-authors of Debra Tompson

This figure shows the co-authorship network connecting the top 25 collaborators of Debra Tompson. A scholar is included among the top collaborators of Debra Tompson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Debra Tompson. Debra Tompson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Stamatopoulos, Konstantinos, et al.. (2025). Physiologically Based Pharmacokinetic Modeling of Phosphate Prodrugs─Case Studies: Fostemsavir and Fostamatinib. Molecular Pharmaceutics. 22(4). 2168–2181. 1 indexed citations
2.
Simeoni, Monica, et al.. (2024). Longitudinal modeling of efficacy response in patients with lupus nephritis receiving belimumab. Journal of Pharmacokinetics and Pharmacodynamics. 51(3). 289–301. 1 indexed citations
3.
Ludbrook, Valerie J., David C. Budd, Debra Tompson, et al.. (2024). Inhibition of Receptor-Interacting Protein Kinase 1 in Chronic Plaque Psoriasis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. Dermatology and Therapy. 14(2). 489–504. 8 indexed citations
4.
Salem, Farzaneh, et al.. (2023). Physiologically based pharmacokinetic modeling for development and applications of a virtual celiac disease population using felodipine as a model drug. CPT Pharmacometrics & Systems Pharmacology. 12(6). 808–820. 4 indexed citations
5.
Tompson, Debra, et al.. (2022). Development of a Once-Daily Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772 using DiffCORE Technology. Pharmaceutical Research. 39(1). 153–165. 10 indexed citations
6.
Tompson, Debra, et al.. (2021). Development of a Prototype, Once-Daily, Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772. Pharmaceutical Research. 38(7). 1235–1245. 10 indexed citations
7.
Tompson, Debra, Carwyn Davies, Nicola Scott, et al.. (2020). Comparison of the Pharmacokinetics of RIPK1 Inhibitor GSK2982772 in Healthy Western and Japanese Subjects. European Journal of Drug Metabolism and Pharmacokinetics. 46(1). 71–83. 18 indexed citations
8.
Schwartzbach, Caryl, Richard Grove, Robert A. Brown, et al.. (2016). Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study. Journal of Neurology. 264(2). 304–315. 86 indexed citations
9.
10.
Tompson, Debra, et al.. (2014). Lack of effect of ezogabine/retigabine on the pharmacokinetics of digoxin in healthy individuals: results from a drug–drug interaction study. Clinical Pharmacology Advances and Applications. 6. 149–149. 5 indexed citations
11.
Tompson, Debra, et al.. (2014). Effect of Hemodialysis on Pharmacokinetics of Ezogabine/Retigabine and its N-Acetyl Metabolite in Patients with End Stage Renal Disease. Current Clinical Pharmacology. 9(4). 319–325. 3 indexed citations
12.
Tompson, Debra & Christopher Crean. (2013). Clinical Pharmacokinetics of Retigabine/Ezogabine. Current Clinical Pharmacology. 8(4). 319–331. 21 indexed citations
13.
Crean, Christopher & Debra Tompson. (2013). The Effects of Ethanol on the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Ezogabine (Retigabine). Clinical Therapeutics. 35(1). 87–93. 12 indexed citations
14.
Tompson, Debra, et al.. (2013). Efficacy and Tolerability Exposure–Response Relationship of Retigabine (Ezogabine) Immediate-Release Tablets in Patients With Partial-Onset Seizures. Clinical Therapeutics. 35(8). 1174–1185.e4. 9 indexed citations
15.
Dixon, Ruth, Sarah A. Job, Ruth Oliver, et al.. (2008). Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects. British Journal of Clinical Pharmacology. 66(3). 396–404. 82 indexed citations
16.
17.
18.
19.
Martin, David E., Debra Tompson, Steven C. Boike, et al.. (1997). Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers. British Journal of Clinical Pharmacology. 43(6). 661–664. 22 indexed citations
20.
Grossman, Jay, Isidore Faiferman, Jeffrey W. Dubb, et al.. (1997). Results of the First U.S. Double-Blind, Placebo-Controlled, Multicenter Clinical Study in Asthma with Pranlukast, a Novel Leukotriene Receptor Antagonist. Journal of Asthma. 34(4). 321–328. 70 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eunice Yuen Breakdown of academic impact, for papers by Ming Sun Breakdown of academic impact, for papers by Danilo Croci Breakdown of academic impact, for papers by Carol Donovan Breakdown of academic impact, for papers by Smita Kshirsagar Breakdown of academic impact, for papers by Maria B. Ræder Breakdown of academic impact, for papers by Rosalin Arends Breakdown of academic impact, for papers by Sandrine Vuillaumier‐Barrot Breakdown of academic impact, for papers by Jozef Hertecant Breakdown of academic impact, for papers by Ugochi Emeribe
Rankless by CCL
2026